|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500102000 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-07 10:50:10 |
|
注册时间: Date of Registration: |
2025-05-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于实施科学的社区结直肠癌筛查数字化干预方案的构建与评估:阶梯设计整群随机对照试验 |
|
Public title: |
Development and Evaluation of a Digital Community-Based Colorectal Cancer Screening Intervention Based on Implementation Science: A Stepped-Wedge Cluster Randomized Controlled Trial |
|
注册题目简写: |
社区结直肠癌筛查数字化干预阶梯设计整群随机对照试验研究 |
|
English Acronym: |
Community CRC Digital Intervention SW-CRT |
|
研究课题的正式科学名称: |
基于实施科学的早起结直肠癌“社区-医院”双主体协同筛查模式的构建及应用 |
|
Scientific title: |
Development and Application of a Community-Hospital Collaborative Screening Model for Early Colorectal Cancer Detection Based on Implementation Science |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
施冰梓 |
研究负责人: |
张静 |
|
Applicant: |
Shi Bingzi |
Study leader: |
Zhang Jing |
|
申请注册联系人电话: Applicant telephone: |
+86 130 3801 1303 |
研究负责人电话:
Study leader's |
+86 137 0481 5852 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1104893754@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
jingzhang1970@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
黑龙江省哈尔滨市南岗区学府路194号 |
研究负责人通讯地址: |
黑龙江省哈尔滨市颐园街37号 |
|
Applicant address: |
No. 194, Xuefu Road, Nangang District, Harbin, Heilongjiang Province, China |
Study leader's address: |
No. 37, Yiyuan Street, Harbin, Heilongjiang Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
哈尔滨医科大学 |
||
|
Applicant's institution: |
Harbin Medical University (HMU) |
||
|
研究负责人所在单位: |
哈尔滨医科大学附属第四医院 |
||
|
Affiliation of the Leader: |
The Fourth Affiliated Hospital of Harbin Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-伦理审查-33 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
哈尔滨医科大学附属第四医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Fourth Affiliated Hospital of Harbin Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-26 00:00:00 | ||
|
伦理委员会联系人: |
王玉珏 |
||
|
Contact Name of the ethic committee: |
Wang Yujue |
||
|
伦理委员会联系地址: |
黑龙江省哈尔滨市颐园街37号 |
||
|
Contact Address of the ethic committee: |
No. 37, Yiyuan Street, Harbin, Heilongjiang Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 451 8257 6558 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
哈尔滨医科大学附属第四医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Fourth Affiliated Hospital of Harbin Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
黑龙江省哈尔滨市颐园街37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 37, Yiyuan Street, Harbin, Heilongjiang Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国社会福利基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
China Social Welfare Foundation |
||||||||||||||||||||||
|
研究疾病: |
结直肠癌 |
||||||||||||||||||||||
|
Target disease: |
Colorectal Cancer (CRC) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
本研究旨在基于实施科学(Implementation Science)理论框架,构建并评估一种社区结直肠癌筛查的数字化干预方案,优化筛查流程,提高筛查参与率和服务效率,为全国推广提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to develop and evaluate a digital intervention program for community-based colorectal cancer screening based on the implementation science framework, optimizing screening processes, increasing participation rates, and improving service efficiency to provide scientific evidence for nationwide implementation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
社区医务人员纳入标准: 已获得执业资格证书; 从事社区癌症筛查相关工作;具备 3 年以上工作经验。 社区居民纳入标准: 年龄为 40~75岁; 社区常住居民, 具备完全行为能力; 无结直肠癌病史, 未接受过结直肠切除手术; 无恶性肿瘤病史, 未患有严重心、 脑、 肺疾病或肾功能障碍。 |
||||||||||||||||||||||
|
Inclusion criteria |
For Community Healthcare Providers: Possession of a valid professional qualification certificate. Engaged in community cancer screening-related work. At least three years of work experience in community healthcare services. For Community Residents: Aged between 40 and 75 years old. Permanent residents of the community with full cognitive and behavioral capacity. No history of colorectal cancer and no prior colorectal resection surgery. No history of malignant tumors. No severe cardiovascular, cerebrovascular, pulmonary diseases, or renal dysfunction. |
||||||||||||||||||||||
|
排除标准: |
社区医务人员:非在岗人员 社区居民:五年内参与过结直肠筛查项目;无具体联系方式。 |
||||||||||||||||||||||
|
Exclusion criteria: |
For Community Healthcare Providers: Not currently employed (inactive staff). For Community Residents: Participated in a colorectal cancer screening program within the past five years. No valid contact information available. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-05-30 00:00:00至 To 2025-11-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-30 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究将采用整群随机对照设计,按社区作为随机化单位进行分配。随机序列由独立统计学家使用SPSS 26.0 随机模块生成,并在干预分配前保持隐藏。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Clusters communities will be randomly assigned to different intervention groups using a cluster randomization method. The random sequence will be generated by an independent statistician using the randomization module in SPSS 26.0. The allocation will be concealed until the intervention is assigned. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
NA |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究完成 6 个月后,研究数据将匿名化并在 Open Science Framework(OSF) 公开,提供数据集、研究方案及相关文档,以供学术研究和政策制定使用。网址:https://osf.io/aws3p/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after study completion, anonymized individual participant data (IPD) will be shared on Open Science Framework (OSF), providing datasets, study protocols, and relevant documents for academic research and policy development. URL: https://osf.io/aws3p/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集包括病例记录表(Case Record Form, CRF)和电子数据采集系统(Electronic Data Capture, EDC)。CRF 用于原始数据记录,而 ResMan/REDCap 将用于数据电子化管理,以提高数据完整性、安全性,并确保符合伦理要求。 研究期间将定期进行数据审核和验证,以确保数据质量和一致性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection will include Case Record Forms (CRF) and an Electronic Data Capture (EDC) system. The CRF will be used for primary data entry, while ResMan/REDCap will manage electronic data to ensure integrity, security, and ethical compliance. Regular data monitoring and validation will be conducted throughout the study to ensure quality and consistency. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |